These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38340060)

  • 1. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
    van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
    J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    Galileya LT; Wasmann RE; Chabala C; Rabie H; Lee J; Njahira Mukui I; Hesseling A; Zar H; Aarnoutse R; Turkova A; Gibb D; Cotton MF; McIlleron H; Denti P
    PLoS Med; 2023 Nov; 20(11):e1004303. PubMed ID: 37988391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
    Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
    Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
    Alsultan A; An G; Peloquin CA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
    Thee S; Garcia-Prats AJ; McIlleron HM; Wiesner L; Castel S; Norman J; Draper HR; van der Merwe PL; Hesseling AC; Schaaf HS
    Antimicrob Agents Chemother; 2014 May; 58(5):2948-51. PubMed ID: 24550337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
    Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.